Stand Up To Cancer 2023 Annual Report

STAND UP TO CANCER 2023 ANNUAL REPORT

COLLABORATION AND INSPIRATION

BRINGING THE PROMISE OF EXPEDITED, NEW TREATMENTS FOR PEOPLE WHO DESPERATELY NEED THEM.

STAND UP TO CANCER 2023 ANNUAL REPORT

WELCOME Dear Friends of Stand Up To Cancer®: As SU2C embarks on its 16th year, I am proud to share the remarkable

progress we’ve made over the past year in our mutual goal to end cancer as we know it.

This year’s inaugural report highlights our recent accomplishments and the strides we have made in advancing cancer research.

During the past year, new SU2C grants focused on gastroesophageal and

head & neck cancers, as well as increasing diversity in cancer clinical trials.

SU2C-funded investigators published exceptional research; an exciting

pancreatic cancer clinical trial was the first to demonstrate an mRNA vaccine for cancer treatment.

SU2C’s eighth biennial telecast aired on August 19 and celebrated SU2C’s impact on collaborative cancer research, and additional awareness efforts included several PSAs and a campaign to launch The Alex Trebek Fund to raise funding for pancreatic cancer research.

Today, we are at an inflection point, with a revitalized Scientific Advisory

Committee, and a new strategic focus on early detection and interception.

We have a bold goal to reduce mortality from cancer by 25 percent in the

next five years! While ambitious, we believe groundbreaking advancements are achievable with immunotherapies that can wipe out cancer; vaccines

that prevent or treat cancer; and preventative research that utilizes AI and large language models to predict and diagnose cancer earlier than ever.

SU2C is indebted to many individuals and organizations for their

long-standing commitment to our mission, including our scientific partner, the American Association for Cancer Research (AACR). We look to

our generous donors for their continued support, united in purpose and

focused on our shared goal of ending cancer as we know it. Thank you for standing with us. All of this is possible with your financial contribution.

Warmly,

Julian Adams, PhD

President and CEO

15 1

A YEAR OF PROGRESS AND CHANGE FOR STAND UP TO CANCER

STAND UP TO CANCER 2023 ANNUAL REPORT

2023 YEAR IN REVIEW As described in the following pages, 2023 was a year of progress and

change for Stand Up To Cancer with new executive and scientific leader-

ship taking the reins while we expanded our translational research portfolio into gastroesophageal cancer. We also launched new teams exploring the role of the human microbiome in cancer and head and neck squa-

mous cell carcinoma. These projects add to a portfolio of cancer research that seeks to create better treatments and new preventive strategies for the vast majority of types of cancers.

Our science collaborations were supported by ongoing public education and awareness events, including our eighth biennial roadblock telecast, which was presented in August on more than 55 participating media

platforms across the United States and Canada, including all four major broadcast networks in the U.S. And new public service campaigns —

reaching audiences in both English and Spanish about the importance of colon cancer screening and other topics — appeared in top print, broadcast, radio, digital and out-of-home outlets. SU2C-supported scientists

and ambassadors also participated in regional and national meetings to raise awareness of cancer breakthroughs and new programs.

At both the All-Star Game in July and again at the World Series in Oc-

tober, SU2C Founding Donor Major League Baseball and SU2C’s iconic placard moments brought the promise of cancer research home to mil-

lions. Similarly, the #SU2CStreamTeam brought together gamers, streamers, and content creators across gaming and social media platforms for

the third annual #Up2Us to Stand Up To Cancer fundraiser. And new collaborations, such as The Alex Trebek Fund announced in November, will help us accelerate critical research with the goal of better treating pan-

creatic cancer, which has the highest mortality rate of all major cancers.

With over $1 million in contributions raised through a generous donation from Jean Trebek, wife of the late Alex Trebek, and the Estate of Barbara Hanania, SU2C is poised to spur new research collaborations in support of patients and families impacted by this deadly disease.

3

STAND UP TO CANCER IS TRANSFORMING CANCER RESEARCH

STAND UP TO CANCER 2023 ANNUAL REPORT

A GROUNDBREAKING MOVEMENT Stand Up To Cancer (SU2C) funds groundbreaking cancer research to

detect, intercept and treat cancers with the aspiration to cure all patients.

Connecting the top minds in science, SU2C has been at the forefront of cutting-edge cancer research for over 15 years. In addition to its core

Dream Team research projects, other scientific initiatives include SU2C Convergence®, uniting biological, physical and computer sciences to

better understand cancer biology and more quickly tailor treatments;

SU2C Catalyst®, bringing together industry and academic scientists to accelerate clinical trials of new treatments and combination therapies; and cancer interception, aiming to find and treat cancer at the earliest

possible point. Funding is also available for individuals and small teams to rapidly explore emerging ideas. These milestone-driven projects are competitively selected and overseen by leaders in cancer research.

An integral part of SU2C’s identity is its relationship with the entertain-

ment community. Over 1,100 celebrity ambassadors support awareness and fundraising efforts including SU2C’s marquee biennial “roadblock”

fundraising telecasts, nearly 100 PSA campaigns and countless education

initiatives, bringing much-needed attention to cancer screening, research, clinical trials and more.

Unique collaborations with donors include yearly campaigns in support of SU2C’s mission and iconic placard moments, where thousands of people stand to honor those impacted by cancer at Major League Baseball’s AllStar and World Series Games.

All of these efforts support research from over 3,000 scientists across 13

countries, impacting hundreds of thousands of people and helping more people impacted by cancer thrive.

5

COLLABORATION. PROGRESS. IMPACT. AS SU2C ACCELERATES CANCER RESEARCH, THE INVESTIGATIONS IT SUPPORTS HAVE THE POTENTIAL TO TRANSFORM THE TREATMENT OF CANCERS IN BOTH ADULTS AND CHILDREN.

Stand Up to Cancer research programs are administered with the assistance of our scientific partner, the American Association for Cancer Research.

STAND UP TO CANCER 2023 ANNUAL REPORT

SU2C’S YEAR IN SCIENCE Stand Up To Cancer research spans a range of approaches and treat-

ments. From cancer prevention and interception to epigenetics and im-

munotherapy, SU2C’s multifaceted research teams and investigations are focused on the most innovative approaches to bring more effective therapies to patients quickly, to increase survivorship and to improve quality

of life for cancer patients and survivors. SU2C research is transforming the treatment of cancers in both adults and children.

In 2023, SU2C funded 12 new scientific projects, including three groups focused on bringing new therapies to clinical trials for the treatment of

gastroesophageal cancer as part of the SU2C-Torrey Coast Gastroesophageal Cancer (GEC) Dream Team Collective. The teams are uniting top researchers to foster new and inclusive cancer research on the causes

and treatments of GEC, mentor a new generation of scientists focused

on GEC, bring new treatments to the clinic and provide medical professionals with tools and materials to better advocate for GEC screening

and treatment with their patients. Scientists at Columbia University Irving Medical Center, Massachusetts General Hospital, Memorial Sloan Ketter-

ing Cancer Center, NYU Langone, and Weill Cornell Medicine are participating in the Dream Team Collective.

SU2C also funded three 2023 Phillip A. Sharp Innovation in Collaboration

Awards — which focus on bringing new perspectives together and encourage the inclusion of early-career investigators — and one SU2C Maverick

Early Career Scientist Award — which is awarded to an investigator early in their career and supports a cutting-edge idea that has great potential to

impact patient care. One of the Phillip A. Sharp Awards includes the Ziskin Prize, which honors legendary Hollywood producer and SU2C co-founder Laura Ziskin, who passed from breast cancer in 2011. Other awards focus

on gastric cancer, head and neck cancers, squamous cell carcinomas, and

how gut microbes could be used in combination with other treatments for future cancer therapies.

We also provided seven community organizations with grants to fund

efforts to increase diversity in early phase cancer clinical trials through the SU2C Diversity In Early Development Clinical Trials Program, supported

by a sponsorship from the Janssen Pharmaceutical Companies of Johnson & Johnson. These community engagement grants support SU2C’s

focus on addressing disparities in oncology clinical trial participation and facilitating the development of new treatments that have the potential

7

to benefit all patients impacted by cancer. The recipients of these grants operate in four cities — Chicago, Dallas, Los Angeles and Philadelphia —

and are deeply connected to communities that are underrepresented in cancer clinical trials.

THROUGHOUT 2023, SU2C-SUPPORTED SCIENTISTS PUBLISHED NEW KNOWLEDGE AND DISCOVERIES TO HELP CREATE AND TEST NEW CANCER TREATMENT STRATEGIES. The SU2C Colorectal Cancer Dream Team showed that rectal cancer

patients whose tumors have specific genetic characteristics (mismatch

repair–deficient/microsatellite instability–high) can be successfully treated with immune checkpoint blockade (anti-PD-1) immunotherapy, sparing

them from the long-lasting and damaging side effects of surgery, chemotherapy and radiation. More than 35 rectal cancer participants who com-

pleted the treatment have exhibited a complete clinical response, and as

a result the National Comprehensive Cancer Network guidelines for rectal cancer have been updated. In addition, the team evaluated 172 patients with Lynch syndrome (the most common form of hereditary colorectal cancer) to guide immunopreventative strategies against the cancer.

The SU2C Gastric Cancer Interception Research Team developed a

blood test measuring the levels of specific cancer-related proteins with

the potential for early detection of gastric cancer and more timely determination of patient responses to cancer treatment. Quickly establishing the effectiveness of a treatment enables physicians to swiftly shift to an

alternative therapy if the initial treatment proves ineffective for the patient.

The SU2C Catalyst Research Team with Support from Bristol Myers

Squibb showed that melanoma patients who did not respond to a single

immunotherapy can benefit from being treated with a combination immunotherapy. The treated patients had significantly longer progression-free survival.

STAND UP TO CANCER 2023 ANNUAL REPORT

SU2C’S YEAR IN SCIENCE

The SU2C Catalyst Research Team with Support from Merck has

been conducting a clinical trial to explore the possibility that combining anti-PD-1 antibodies with radiation can improve outcomes for patients facing metastases to the lung after a diagnosis of high-risk soft tissue

sarcoma. To test the strategy for patients with this rare cancer, a clinical trial has opened at 20 sites across the U.S. and other nations.

For children with some brain and solid tumors, the SU2C Catalyst

Research Team with support from Bristol Myers Squibb led the first

prospective pediatric trial using treatments approved for other cancers for refractory non-blood based cancers with a high tumor mutation

burden and/or mis-match repair deficiency. The study showed durable responses and prolonged survival.

As part of the SU2C Convergence 3.1416 Team, scientists have har-

nessed the power of a common and benign skin bacteria, Staphylococcus epidermidis, to express a foreign antigen found in melanoma cells. When these bacteria were applied to the skin of mice, they promoted cellular

immunity. This result has major implications in the field of cancer immunology and beyond.

9

And Stand Up To Cancer’s long-standing support of novel therapies for pancreatic cancer resulted in numerous findings.

The SU2C-Lustgarten Foundation Convergence 2.0 Team is investigating how neoantigen-stimulated T cells may impact outcomes in patients

with pancreatic ductal adenocarcinoma (PDAC). To accomplish this task,

the team has developed mRNA vaccines tailored to each patient’s mutational signature and engineered a rapid custom vaccination platform to expedite production. The team completed a successful phase I clinical

trial in which 8 of 16 patients treated with the vaccine plus chemotherapy following surgery experienced prolonged complete response. In fur-

ther research, the team plans to identify reasons for vaccine success and failure and has opened a phase II randomized trial of mRNA neoantigen vaccines in PDAC.

STAND UP TO CANCER 2023 ANNUAL REPORT

SU2C’S YEAR IN SCIENCE The Pancreatic Cancer Collective Molecularly Targeted Radionuclide Therapy New Therapies Challenge Research Team is conducting a

phase I clinical trial to explore the potential of using two new radiopharmaceuticals to diagnose and treat pancreatic cancer targeting the αVβ6 protein found at the surface of pancreatic cancer cells but undetectable on normal cells.

The Pancreatic Cancer Collective Immunotherapy Targeting Mutant

KRAS New Therapies Challenge Research Team is currently conducting experiments required by the U.S. Food and Drug Administration to

confirm the efficacy and specificity of a T-cell receptor against pancreatic cancer progression and has developed a procedure for large-scale production of mKRAS TCR-specific T cells.

In exciting prevention research, the SU2C-Lustgarten Foundation

Pancreatic Cancer Interception Dream Team showed the power of us-

ing remote strategies to encourage those who have increased familial risk of pancreatic cancer to undergo genetic screening. The team observed

that when an easy-to-use genetic screening kit is provided, along with the option for online education and guidance from a healthcare team, family members of pancreatic cancer patients are more willing to undergo

genetic screening to determine whether they have an increased risk of developing pancreatic cancer.

Finally, 2023 SU2C Maverick Award winner Alexander Pearson, MD, PhD, from the University of Chicago, used his funding to combine head and

neck cancer molecular information and digital pathology images. Nota-

bly, he built a $200 microscope which allows for digital pathology diagnosis and has the potential for high impact globally, including in developing countries who may lack significant clinical infrastructure.

11

RELENTLESS AND DETERMINED

STAND UP TO CANCER WORKS RELENTLESSLY TO OFFER THE NEWEST, MOST EFFECTIVE AND MOST PROMISING CANCER TREATMENTS TO PATIENTS QUICKLY.

STAND UP TO CANCER 2023 ANNUAL REPORT

SUPPORTING PATIENTS Stand Up To Cancer works relentlessly to offer the newest, most effective

and most promising cancer treatments to patients quickly. To date, more than 29,000 cancer patients have participated in SU2C-funded clinical trials, many more have found information about cancer research on

our website, and patients serve as advocates and advisors on all SU2C

scientific teams. Three patient stories featured on the 2023 SU2C Telecast illustrate how our cancer research is impacting people now.

KELLY SPILL: RECTAL CANCER

New Jersey resident Kelly Spill participated in a SU2C-funded clinical trial by the SU2C Colorectal Cancer Dream Team, receiving immunotherapy for Stage 3 rectal cancer to test whether the standard chemotherapy,

radiation, and surgery protocols could be avoided. Just the fourth person in the country to participate in the trial, Kelly’s tumor began to shrink and after nine cycles of treatment it was gone completely. After treatment, Kelly was able to get pregnant and had a baby girl.

KELLIE AND YAPHET SMITH: MULTIPLE MYELOMA

When his wife Kellie experienced severe back pain and was diagnosed

with multiple myeloma, Texan Yaphet Smith enrolled in the SU2C Multiple Myeloma Dream Team’s PROMISE Study. This was the first study to test

healthy people who may be at risk for early warning signs, or precursors, of a blood cancer called multiple myeloma, which can often run in fami-

lies. Yaphet’s participation in the study confirmed that he did not have the early warning signs, meaning Kellie and Yaphet’s child is at less of a risk for multiple myeloma.

ELIZABETH O’CONNOR: PANCREATIC CANCER

Elizabeth O’Connor of Georgia was 31 years old and had just given birth

to her second child when diagnosed with Stage 4 pancreatic cancer. Over nearly 13 years, Elizabeth has experienced metastases and has under-

gone many treatments, including two treatments developed by Stand Up

To Cancer-funded pancreatic cancer researchers: targeted chemotherapy and immunotherapy. Immunotherapy has been a pivotal treatment for Elizabeth, who is thriving and enjoying life with her family.

13

CELEBRATING 15 YEARS

CELEBRITIES, CANCER SURVIVORS AND SCIENTISTS JOIN STAND UP TO CANCER FOR EIGHTH ROADBLOCK TELECAST.

STAND UP TO CANCER 2023 ANNUAL REPORT

THE SU2C TELECAST Stand Up To Cancer’s eighth biennial telecast aired on August 19, 2023, and was a celebration of cancer survivorship and scientific breakthroughs inspiring hope for a day when all cancer patients will be long-term survivors.

The televised special was emceed by SU2C Co-founder Katie Couric

and aired simultaneously on more than 55 participating media platforms across the United States and Canada, including all four major broadcast networks in the U.S.

Memorable moments included a personal message from President Joe Biden and First Lady Dr. Jill Biden, inspirational stories from cancer sur-

vivors and SU2C-funded researchers, and a special montage of comedic skits and musical performances from past shows. Celebrities lending

their support for this year’s fundraising special included Elizabeth Banks, Jessica Biel, Don Cheadle, Danai Gurira, Tony Hale, Ken Jeong, Queen

Latifah, Maria Menounos, Julianne Moore, Tig Notaro, Jimmy Smits, Eric Stonestreet and Justin Timberlake, to name a few.

During the telecast, SU2C announced a special campaign with American

Airlines in which AAdvantage® members could contribute and earn miles

for every dollar donated. In a video featured during the telecast, American Airlines Chief Executive Officer Robert Isom and several American team

members reflected on the airline’s collaboration with and commitment to the long-standing relationship with SU2C.

Following the telecast, SU2C announced that since being founded in

2008, nearly $800 million has been pledged to fund critically needed cancer research.

15

HELP CANCER PATIENTS MAKE NEW MEMORIES FOR YEARS TO COME Stand Up To Cancer, with support from Visit Myrtle Beach, is working to push progress forward to find new and better treatments so cancer patients can thrive.

Join this mission at StandUpToCancer.org

Matthew McConaughey Stand Up To Cancer Ambassador

Photo by John Russo Background Photo by Bobby Altman

STAND UP TO CANCER IS A 501(C)(3) CHARITABLE ORGANIZATION.

© 2024 Fox Media LLC. CR: Kevin Estrada/FOX

RAISING AWARENESS WITH FAMILIAR FACES

BRINGING THE PROMISE OF CANCER RESEARCH AND PROMOTING PREVENTION SERVICES TO GENERAL AND TARGETED AUDIENCES THROUGH DONATED AND EARNED MEDIA.

STAND UP TO CANCER 2023 ANNUAL REPORT

CELEBRITY AMBASSADORS, PSAs & MEDIA Each year SU2C produces and places national public awareness campaigns across top print, broadcast, radio, digital and out-of-home outlets. SU2C was also featured in over 4,800 news stories, including segments on

Good Morning America, Today, and CNN, and in national media outlets, including Forbes, Parade, and USA Today. In 2023 SU2C brought the

promise of cancer research, and the need for people to seek preventative services, to the public with the help of celebrities such as will.i.am, George Lopez, and Matthew McConaughey. Appearing in more than $302 million of donated ad space, the campaigns garnered over 8.3 billion media impressions.

WHY WE DO THIS: LET’S TALK COLON CANCER

English- and Spanish-language PSAs featured Grammy®-winning mu-

sician will.i.am and stand-up comedian and actor George Lopez raised

awareness in medically underserved communities about colorectal cancer screenings and early detection and prevention, part of an ambitious

national project on colorectal cancer disparities supported by SU2C, Providence Saint John’s Health Center, and Exact Sciences.

LIFE DISRUPTED: A FAMILY’S EXPERIENCE WITH CANCER

Academy Award®-winning actor Matthew McConaughey joined SU2C and Visit Myrtle Beach for a new public service announcement raising awareness about the importance of cancer research. The campaign

features McConaughey narrating poignant memories for a family that

frequently visits the beach as the father experiences a cancer diagnosis.

WHAT MOTIVATES SCIENTISTS: IT’S ALL IN THE WHY

SU2C’s scientific leaders and funded researchers spoke to the motivation and inspiration behind their work, sharing their goals to have a positive impact on people affected by cancer. In this PSA, SU2C united leading

voices from the cancer research community to emphasize the importance of funding groundbreaking cancer research.

In addition, Stand Up To Cancer was featured in influencer campaigns

across social media, and on TV shows such as Jeopardy!, Wheel of Fortune, Celebrity Name That Tune, and 9-1-1: Lone Star.

17

GENERATING AWARENESS ALL YEAR LONG

WE SPREAD THE MESSAGE ABOUT GROUNDBREAKING CANCER RESEARCH WITH OUR PARTNERS IN SPORTS, ENTERTAINMENT, GAMING, AND MORE.

STAND UP TO CANCER 2023 ANNUAL REPORT

SU2C IN THE COMMUNITY Stand Up To Cancer works around the country, with the support of donor and entertainment collaborators, to spread the message about the hope that translational cancer research brings to so many people.

At both the All-Star Game and at the World Series this year, SU2C Founding Donor Major League Baseball honored people impacted by cancer and the promise of cancer research through iconic SU2C placard mo-

ments. During the games, tens of thousands of fans, players, umpires,

and stadium staff paused to acknowledge someone important to them

who has contended with cancer. Many more participated at home. And at baseball, hockey and Night Nation Run events around the country more people than ever are helping to support translational cancer research.

Mastercard continued its longstanding support of SU2C, as well. Along

with Academy Award® winner and SU2C Ambassador Jennifer Hudson,

the company encouraged consumers to make a difference by using their

Mastercard when ordering online or tapping their card at restaurants and grocery stores. Consumers across the country supported the campaign.

SU2C-supported scientists and ambassadors also participated in meetings to raise awareness. In February, SU2C Ambassador Sonequa Martin-Green spoke at the FDA’s Oncology Center of Excellence program commemorating Black History Month. And SU2C Ambassador Chandra Wilson

participated in the FDA Oncology Center of Excellence’s Conversations

on Cancer: Engaging the Generations discussion in June to kick off Black

Family Cancer Awareness Week, discussing how providers and advocates can reach the Black community to increase screening rates and improve clinical trials participation.

Also in 2023, the #SU2CStreamTeam celebrated the success of its third #Up2Us to Stand Up To Cancer event. #Up2Us capitalizes on the skills

of gamers, streamers and content creators across platforms, including Twitch, TikTok, Facebook, Instagram and YouTube. The #SU2CStream-

Team’s ability to inspire year-round engagement and contributions exemplifies the significant role this community will play in cancer research and support for generations to come.

19

2023 FINANCIALS REVENUE EXCLUDING GIFTS-IN-KIND

INCLUDING GIFTS-IN-KIND

NOTES: Information reflects unaudited financials. *Net revenue from SU2C biennial televised fundraising event. **Value of media donated to SU2C to air public service announcements. ***In-kind contribution of merchandise and services, including airline miles to support its programs.

Financial audit in progress at the time of publication.

Audited financial statements will be available upon completion.

$29,385,052 $10,287,608 $6,895,394

EVENTS*

DIRECT CONTRIBUTIONS (PUBLIC)

CORPORATE AND FOUNDATION CONTRIBUTIONS IN-KIND CONTRIBUTIONS (MEDIA)**

$29,385,052 $10,287,608 $6,895,394 $ 212,009,351

IN-KIND CONTRIBUTIONS (OTHER)***

$1,378,842

$334,483

INVESTMENT INCOME

$334,483

$46,902,537

TOTAL REVENUE

$260,290,730

STAND UP TO CANCER 2023 ANNUAL REPORT

2023 FINANCIALS EXPENSES EXCLUDING GIFTS-IN-KIND 64.9% 11.0% 13.4%

75.9%

PROGRAM SERVICES

10.7%

24.1%

SUPPORTING SERVICES

INCLUDING GIFTS-IN-KIND

9.9%

1.7%

11.7%

SUPPORTING SERVICES

77.8% 10.5%

88.3% PROGRAM SERVICES

$27,722,743

PROGRAM SERVICES GRANT PROGRAM

$27,722,743

$4,701,978

PUBLIC AWARENESS AND EDUCATION

$205,297,925

$4,575,907

SUPPORTING SERVICES MANAGEMENT AND GENERAL

$4,575,907

$5,735,921

FUNDRAISING

$26,163,067

$42,736,549

TOTAL EXPENSES

$263,759,643

21

MOVING CANCER SCIENCE FORWARD

AS STAND UP TO CANCER LOOKS TOWARD 2024 AND BEYOND, WE WILL CONTINUE TO ENSURE WE ARE FUNDING THE MOST PROMISING AND IMPACTFUL CANCER RESEARCH.

STAND UP TO CANCER 2023 ANNUAL REPORT

SU2C IN 2024 Considering the advancements in early detection of cancer and pre-cancerous lesions, along with a better understanding of risk factors and screening tools, it is possible to imagine that early intervention and

interception will dramatically reduce cancer deaths over the next five to

ten years. Collaborative, bold science will need to be funded to make this vision come true and avert millions of cases of cancer.

New computing tools, including artificial intelligence (AI) and large

language models (LLM) will be critical to accelerating advancements in

cancer care. Given today’s immense computing power and advancements in bioinformatics, non-invasive bio-analytical analyses, electronic medical records, and wearable monitors, the challenge lies with the accuracy and sensitivity of such diagnostic tests. Our Dream Team model is ready to

take on these challenges, helping scientists and clinicians eventually cure cancers, one malignancy at a time. And if achieved, healthcare inequities will also be addressed.

Another emerging field of treatment and prevention is early clinical re-

search with cancer vaccines, which Stand Up To Cancer scientific collaborations have already pioneered in pancreatic cancer. Neoantigens of

tumors can now be identified, and mRNA can be manufactured. Peptides and vaccine delivery technologies are now enabling clinical trials to treat minimal residual disease with promising results.

Our 15-year history of creating impactful collaborative science to get

new treatments to patients quickly means Stand Up To Cancer has the

experience and culture to effectively bring these new tools to bear on a wide variety of cancers. Each cancer type will have unique challenges,

and drug discovery and development continue to produce remarkable treatment options, including small molecule drugs and biologic drugs.

Our pledge is to help push this promising research forward with as much speed as possible.

23

HOW YOU CAN HELP

PLEASE JOIN OUR NETWORK OF SCIENTISTS, PATIENTS, PATIENT ADVOCATES AND CLINICAL TRIAL PARTICIPANTS WHO HAVE COME TOGETHER TO CREATE THE SUCCESSES THAT DEFINE STAND UP TO CANCER.

STAND UP TO CANCER 2023 ANNUAL REPORT

SUPPORTING SU2C DONATE ONLINE Make a onetime

FUNDRAISE FOR STAND UP TO CANCER

Fundraising events

donation or set up

can show how you

a monthly gift via

and your school,

credit card.

business, or community stand up to cancer. We have various tools and

Use your Donor-

materials to get you started and keep

Advised Fund to

you going.

support SU2C.

DONATE AND EARN AMERICAN AIRLINES AADVANTAGE® MILES

Earn airline miles while supporting cancer research.

Donate $25 or more, and you’ll receive

CHARITABLE LIVESTREAM Join the #SU2C-

StreamTeam to raise funds for cancer research in the streaming and gaming community.

GIFTS THAT GIVE BACK

Visit our store to

American Airlines AAdvantage® miles

shop new arrivals

for every dollar you donate. Additional

and personalized

terms apply.

products while

MAIL A CHECK

supporting our collaborative cancer research.

Please make checks payable to Stand Up To Cancer. If you would like to in-

Other ways to

clude a tribute to a friend or loved one,

support Stand Up

you can indicate this in a note enclosed

To Cancer include

with your check. Mail checks to: Stand

planned or estate

Up To Cancer, P.O. Box 843721, Los An-

giving as well as

geles, CA 90084-3721. We’ll send you

donations of securities, cryptocurrency,

an acknowledgment of your gift.

vehicles, and real estate. Visit https:// standuptocancer.org/ways-to-give/ or open the QR code to learn more. You can also email support@su2c.org.

25

EXPERIENCE AND EXPERTISE

OUR TALENTED LEADERS ARE THE DRIVING FORCE BEHIND SU2C’S MISSION. THESE PASSIONATE INDIVIDUALS ARE DEDICATED TO ACCELERATING CANCER RESEARCH AND ENABLING REVOLUTIONARY DISCOVERIES.

STAND UP TO CANCER 2023 ANNUAL REPORT

SU2C LEADERSHIP BOARD OF DIRECTORS

EXECUTIVE TEAM

The Sherry Lansing Foundation

President and CEO

Sherry Lansing, Chairperson

Julian Adams, PhD

Jeff Bader, Secretary

Shawn Burke

Peter Seymour, Treasurer

Dana Hirsch Lipman

NBC Entertainment

Douglas Emmett

Chief Financial Officer

General Counsel

Susan Desmond-Hellmann, MD Phillip A. Sharp, PhD

Massachusetts Institute of Technology Russell Chew , DDS

FOUNDERS & ADVISORS COMMITTEE Katie Couric

Sherry Lansing Kathleen Lobb Lisa Paulsen

Rusty Robertson Sue Schwartz

Pamela Oas Williams Ellen Ziffren

In Remembrance Noreen Fraser Laura Ziskin

27

SCIENTIFIC ADVISORY COMMITTEE William G. Nelson, MD, PhD Chairperson

Johns Hopkins University John D. Carpten, PhD Vice Chairperson

City of Hope National Medical Center Arnold J. Levine, PhD Vice Chairperson

Institute for Advanced Study

MEMBERS

Carlos L. Arteaga, MD

UTSW Harold C. Simmons Cancer Center

Michael A. Caligiuri, MD

City of Hope National Medical Center Steven Carr, PhD Broad Institute

Jenny C. Chang, MD

Houston Methodist Hospital Alan D. D’Andrea, MD

Dana-Farber Cancer Institute Luis A. Diaz, Jr., MD

Memorial Sloan Kettering Cancer Center

S. Gail Eckhardt, MD

Baylor College of Medicine

STAND UP TO CANCER 2023 ANNUAL REPORT

Michael Fischbach, PhD Stanford University

Judy Garber, MD, MPH

Dana-Farber Cancer Institute Richard B. Gaynor, MD BioNTech

Laurie H. Glimcher, MD

Dana-Farber Cancer Institute Nancy F. Goodman, JD Kids v Cancer

James L. Gulley, MD, PhD National Cancer Institute

Michael B. Kastan, MD, PhD Duke Cancer Institute

David Kaufman, MD, PhD Third Rock Ventures

SU2C LEADERSHIP David G. Kirsch, MD, PhD

Laura K. Shawver, PhD

Guillermina (Gigi) Lozano, PhD

Peter Sorger, PhD

Princess Margaret Cancer Centre

University of Texas MD Anderson Cancer Center

Lecia Sequist, MD, MPH Harvard Medical School

Capstan Therapeutics

Harvard Medical School David A. Tuveson, MD, PhD

Cold Spring Harbor Laboratory

Arlene Sharpe, MD, PhD Harvard Medical School

EMERITUS MEMBERS

Elizabeth H. Blackburn, PhD

Andre Nussenzweig, PhD

Lisa Diller, MD

Roderic I. Pettigrew, PhD, MD

William N. Hait, MD, PhD

Cecil B. Pickett, PhD

University of California, San Francisco

Dana-Farber Cancer Institute

Janssen, Pharmaceutical Companies of Johnson & Johnson

William G. Kaelin, Jr., MD

Dana-Farber Cancer Institute Tak W. Mak, PhD

University of Toronto

National Cancer Institute

Texas A&M University

Biogen Inc.

Carol L. Prives, PhD

Columbia University Phillip A. Sharp, PhD

Massachusetts Institute of Technology

29

HEALTH EQUITY COMMITTEE John D. Carpten, PhD

Guillermina (Gigi) Lozano, PhD

City of Hope

Cancer Center

Chairperson

Andrew T. Chan, MD, MPH Harvard Medical School

Margaret Foti, PhD, MD (hc) American Association for Cancer Research

Shawna Hudson, PhD

University of Texas MD Anderson

William G. Nelson, MD, PhD

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University

John Whyte, MD, MPH WebMD

Rutgers Robert Wood Johnson

Raymond M. Williams, JD

Chanita Hughes-Halbert, PhD

David R. Wilson, PhD

Medical School

Norris Comprehensive Cancer Center, University of Southern California

Elizabeth M. Jaffee, MD

DLA Piper

University of North Dakota Karen M. Winkfield, MD, PhD Meharry-Vanderbilt Alliance

Sidney Kimmel Comprehensive

Robert A. Winn, MD

University

Center, Virginia Commonwealth

Cancer Center, Johns Hopkins

STAND UP TO CANCER 2023 ANNUAL REPORT

Massey Comprehensive Cancer University

KEEP CONNECTED TO LEARN MORE ABOUT STAND UP TO CANCER Follow us on social media at:

@SU2C @SU2CScience

@SU2C

@SU2C

please visit us at: www.StandUpToCancer.org Sign up on our homepage to receive our e-newsletter “Behind The Scenes With Stand Up To Cancer”

31

THANKS TO OUR DONORS LUMINARIES

VISIONARIES

HEROES

THANKS TO OUR DONORS

L

CHAMPIONS

EG

AC Y

C I RC

LE

CONTRIBUTORS

INTERNATIONAL SUPPORTERS & COLLABORATORS